Trial Profile

RandomizEd Dabigatran Etexilate Dose Finding Study in Patients With Acute Coronary Syndromes Post Index Event With Additional Risk Factors for Cardiovascular Complications Also Receiving Aspirin and Clopidogrel: Multi-Centre Prospective Placebo Controlled Cohort Dose Escalation Study (RE-DEEM)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 06 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dabigatran etexilate (Primary)
Indications Acute coronary syndromes; Cardiovascular disorders; Embolism and thrombosis
Focus Adverse reactions; Registrational
Acronyms RE-DEEM; RE-VOLUTION
Sponsors Boehringer Ingelheim Pharmaceuticals

15 Mar 2012 Planned number of patients changed from 1878 to 2220 as reported by European Clinical Trials Database.
07 May 2011 Results published in the European Heart Journal.
14 Nov 2009 Results were presented at the 82nd Annual Scientific Sessions of the American Heart Association.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com